MOLN

Bullish

Molecular Partners AG to Present MP0712 Phase 1/2a Study Findings at 2026 ASCO and SNMMI Annual Meetings

Molecular Partners AG announced it will present trial-in-progress posters for its Phase 1/2a study of MP0712, a targeted alpha radiotherapy candidate,...

Quiver Quantitative 50 mins ago 0

Bullish

New targeted lung cancer drug MP0712 reaches patients in US trial

Molecular Partners (NASDAQ: MOLN) announced that its DLL3-targeting radio-DARPin MP0712 is now dosing patients in a US Phase 1/2a trial for small cell...

Stock Titan 49 mins ago 0